Fabior (Tazarotene) Patent Expiration, LOE Window & CMS Spending

Fabior (Tazarotene) by Mayne: FDA Orange Book LOE 2030-02-24, 8 AB generics, $133K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN202428 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-02-24
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$133K
2024 Medicare Part D Spend$34K
2024 Medicaid Spend$99K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel